<DOC>
	<DOCNO>NCT01381705</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict well patient respond treatment . PURPOSE : This research study study biomarkers predict response rituximab treatment sample patient indolent follicular lymphoma .</brief_summary>
	<brief_title>Biomarkers Predicting Response Rituximab Treatment Samples From Patients With Indolent Follicular Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Genotype full cohort sample available RESORT clinical trial ( ECOG-E4402 ) FCGR3A 158V/F parallel independently verify result . - Correlate FCGR3A 158V/F polymorphism response , response duration , time rituximab resistance . Secondary - Quantify copy number variation FCGR3A cohort . OUTLINE : Archived DNA sample isolate peripheral blood mononuclear cell formalin-fixed paraffin-embedded tissue sample analyze FCGR3A 158V/F polymorphism use different complementary genotyping method . Assay result review compare patient ' outcome data .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed indolent follicular lymphoma Treated RESORT trial ( ECOGE4402 ) comprise rituximab monotherapy randomize rituximab maintenance therapy retreatment rituximab upon disease relapse Blood tissue sample patient available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
</DOC>